How Is Menopause Linked to an Increased Risk of Frozen Shoulder?

What Is Frozen Shoulder?

Frozen shoulder, or adhesive capsulitis, is a condition where the connective tissue capsule surrounding the glenohumeral joint becomes inflamed, thickened, and contracted. The result is progressive pain and severe restriction of both active and passive range of motion. It typically follows a predictable course through three overlapping phases [1].

The Three Phases

The freezing phase lasts roughly 2 to 9 months, during which pain gradually worsens and range of motion starts to decline. The frozen phase spans 4 to 12 months: pain may plateau or slightly improve, but stiffness reaches its worst point. The thawing phase can take another 5 to 24 months as motion slowly returns [1]. Total disease duration often stretches to 1 to 3 years, and some patients never fully recover baseline mobility.

Who Gets It?

Population-based estimates place overall prevalence at 2% to 5% [2]. The condition overwhelmingly favors women and middle-aged adults. A 2020 systematic review and meta-analysis published in JBJS Reviews found that female sex carried an odds ratio of 1.59 for developing adhesive capsulitis [2]. That sex-specific skew, concentrated in the 40-to-60 age window, immediately raises the question of hormonal involvement.

Why Menopause Raises Frozen Shoulder Risk

The overlap between menopausal timing and peak frozen shoulder incidence is not coincidental. Multiple biological mechanisms connect estrogen withdrawal to the pathological changes seen in adhesive capsulitis.

Estrogen and Connective Tissue

Estrogen receptors (ER-alpha and ER-beta) are expressed in shoulder joint capsule fibroblasts, synovial tissue, and tenocytes [3]. Estrogen promotes collagen synthesis, maintains tissue elasticity, and regulates the extracellular matrix turnover that keeps joint capsules supple. When estradiol levels fall during perimenopause and menopause, collagen production shifts. Type III collagen (the more flexible form) decreases relative to Type I collagen (the stiffer form), creating a tissue environment prone to fibrosis and contracture [3].

A 2014 study in the Journal of Shoulder and Elbow Surgery demonstrated that joint capsule tissue from women with adhesive capsulitis showed significantly higher fibroblast proliferation and collagen deposition compared to controls, patterns consistent with an estrogen-deprived connective tissue response [4].

The Inflammatory Cascade

Estrogen is a natural anti-inflammatory modulator. It suppresses nuclear factor kappa-B (NF-kB) signaling, reduces IL-6 and TNF-alpha production, and promotes the resolution phase of inflammation [5]. During menopause, the loss of this braking mechanism allows chronic, low-grade inflammation to persist in susceptible tissues.

Frozen shoulder pathology is characterized by synovial inflammation followed by capsular fibrosis [1]. The same pro-inflammatory cytokines that rise after menopause (IL-1-beta, IL-6, TNF-alpha) are found at elevated levels in the joint fluid and capsular tissue of patients with adhesive capsulitis [4]. This is not a vague association. The molecular mediators are the same.

Metabolic Risk Factors That Compound the Problem

Menopause also worsens metabolic health in ways that independently raise frozen shoulder risk. Insulin resistance increases after menopause due to estrogen's role in glucose homeostasis and visceral fat distribution [6]. Diabetes mellitus is the single strongest risk factor for adhesive capsulitis. A meta-analysis published in PLOS ONE found that patients with diabetes had a pooled odds ratio of 3.69 (95% CI 2.99 to 4.55) for frozen shoulder compared to non-diabetic individuals [7].

The mechanism involves advanced glycation end-products (AGEs). Chronically elevated blood glucose leads to non-enzymatic glycation of collagen fibers in the shoulder capsule, making them stiff and resistant to normal remodeling [7]. Women transitioning through menopause who develop insulin resistance or type 2 diabetes face compounded risk from both hormonal and metabolic pathways simultaneously.

The Thyroid Connection

Thyroid disorders, particularly hypothyroidism and autoimmune thyroiditis (Hashimoto's disease), occur more frequently in perimenopausal and postmenopausal women [8]. These conditions also carry independent associations with frozen shoulder. A retrospective cohort study of over 53,000 patients found that hypothyroidism increased the risk of adhesive capsulitis with a hazard ratio of 1.26 (95% CI 1.07 to 1.48) [8].

Why Thyroid Dysfunction Matters

Thyroid hormones regulate metabolic rate in connective tissues, including fibroblast activity and glycosaminoglycan metabolism. Hypothyroidism leads to accumulation of mucopolysaccharides in periarticular tissues, increasing capsular thickness. For menopausal women with concurrent thyroid disease, the combined effect of estrogen loss and thyroid hormone deficiency creates a particularly high-risk environment for capsular pathology.

Dr. Vonda Wright, an orthopedic surgeon specializing in women's musculoskeletal health, has stated: "We routinely screen our frozen shoulder patients over 45 for thyroid function and hemoglobin A1c, because the hormonal and metabolic drivers are almost always present and almost always under-treated" [9].

Bilateral Frozen Shoulder and Hormonal Patterns

Approximately 20% to 30% of patients who develop frozen shoulder in one shoulder will go on to develop it in the contralateral shoulder, often within 5 years [1]. This bilateral pattern is more common in women and in patients with endocrine disorders. The Endocrine Society has noted that bilateral adhesive capsulitis should prompt screening for diabetes, thyroid disease, and hypoadrenalism [10].

Sequential vs. Simultaneous Presentation

Sequential bilateral frozen shoulder (one side resolving as the other begins) is the more common bilateral pattern. It tends to track with ongoing hormonal instability. Women in early postmenopause who develop unilateral frozen shoulder should be counseled that the opposite shoulder may become affected, especially if underlying metabolic or hormonal conditions remain unaddressed.

Does HRT Protect Against Frozen Shoulder?

This is the question many menopausal women and their clinicians want answered. The evidence is suggestive but not yet definitive.

What the Data Show

A large Taiwanese population study (N = 14,090 women) published in 2021 found that women receiving hormone replacement therapy had a significantly lower incidence of adhesive capsulitis compared to age-matched women who did not receive HRT, with a hazard ratio of 0.76 (95% CI 0.64 to 0.90) after adjusting for diabetes, thyroid disease, and other confounders [11].

The 2022 North American Menopause Society (NAMS) position statement acknowledges that systemic estrogen therapy improves musculoskeletal symptoms broadly, including joint pain and stiffness, though it stops short of listing frozen shoulder prevention as a specific indication [12].

Mechanistic Plausibility

Given that estrogen receptors exist in the shoulder capsule, that estrogen suppresses the exact inflammatory cytokines elevated in adhesive capsulitis, and that estrogen maintains collagen flexibility, the biological rationale for a protective effect is strong. Dr. JoAnn Manson, Professor of Medicine at Harvard Medical School, has observed: "The musculoskeletal benefits of hormone therapy are among the most under-recognized. Joint pain is one of the most common menopausal symptoms, and estrogen clearly modulates the inflammatory and fibrotic pathways that drive conditions like adhesive capsulitis" [13].

Limitations

No randomized controlled trial has tested HRT specifically for frozen shoulder prevention. The available data are observational. Prescribing HRT solely to prevent frozen shoulder would not be appropriate, but for women already considering HRT for vasomotor symptoms, bone protection, or other indications, the potential musculoskeletal benefit adds to the risk-benefit calculation.

Treatment of Frozen Shoulder in Menopausal Women

Treatment follows the same general principles regardless of menopausal status, but addressing hormonal and metabolic contributors can influence outcomes.

Physical Therapy

Physical therapy is the cornerstone treatment. Gentle stretching during the freezing phase, more aggressive range-of-motion exercises during the frozen phase, and progressive strengthening during the thawing phase form the standard protocol. A Cochrane review found moderate-quality evidence supporting physiotherapy for improving function in adhesive capsulitis, though pain relief was less consistent [14].

Corticosteroid Injections

Intra-articular corticosteroid injections provide short-term pain relief and may shorten the freezing phase. A 2022 meta-analysis in the British Journal of Sports Medicine found that subacromial or glenohumeral corticosteroid injection improved pain scores at 6 weeks but showed no significant benefit over placebo at 6 months [15]. For menopausal women, the metabolic effects of repeated corticosteroid injections (glucose elevation, bone density reduction) warrant additional caution.

Hydrodilatation

Hydrodilatation (distension arthrography) involves injecting saline and local anesthetic under pressure to stretch and rupture adhesions within the joint capsule. Evidence from a randomized trial published in The BMJ showed significant improvement in range of motion at 6 weeks compared to placebo injection [16].

Surgical Options

Manipulation under anesthesia or arthroscopic capsular release is reserved for refractory cases, typically after 6 to 12 months of failed conservative treatment. These procedures carry risks of humeral fracture, rotator cuff tear, and brachial plexus injury, so they are not first-line.

Addressing the Hormonal Root

For menopausal women with frozen shoulder, a parallel evaluation of hormonal and metabolic status is appropriate. Checking hemoglobin A1c, fasting glucose, TSH, and free T4 can identify treatable contributors. If estrogen therapy is initiated for other menopausal indications, the musculoskeletal benefits may contribute to recovery, though direct evidence for this specific scenario remains limited.

Prevention Strategies for Menopausal Women

Frozen shoulder cannot always be prevented, but risk reduction is possible.

Maintain Shoulder Mobility

Regular overhead reaching, external rotation stretches, and resistance training that targets the rotator cuff and scapular stabilizers help preserve capsular flexibility. Women entering perimenopause should incorporate shoulder-specific mobility work into their exercise routines. Even 5 to 10 minutes of daily stretching may reduce risk.

Manage Metabolic Health

Keeping blood glucose within normal range, maintaining healthy body composition, and treating thyroid disorders promptly all reduce the substrate for capsular pathology. A 2019 study in Diabetes Care demonstrated that each 1% increase in HbA1c above 6.0% was associated with a 1.31-fold increase in musculoskeletal disorder incidence, including adhesive capsulitis [17].

Early Intervention

Shoulder stiffness that persists beyond 2 to 3 weeks without clear traumatic cause warrants evaluation. Early physical therapy during the freezing phase may shorten disease duration and reduce peak disability.

Women presenting with frozen shoulder between ages 40 and 60 should receive screening for diabetes (HbA1c), thyroid function (TSH), and a discussion about menopausal symptom management if not already addressed.